TheNewswire – March 31, 2020 – Cultivar Holdings Inc. (CSE:CULT) (CNSX:CULT.CN) (OTC:CVRHF) is pleased to announce that its common shares are now trading on the OTCQB Venture Marketplace (the “OTCQB Venture”), a US trading platform that is operated by the OTC Markets Group in New York. The Company is trading on the OTCQB Venture under symbol “CVRHF”; the Company’s common shares will continue to trade on the Canadian Securities Exchange under the symbol “CULT”.
“Listing on the OTCQB Venture is part of a long-term strategy to introduce our PredictMedix artificial intelligence technologies targeting impairment and healthcare to a broader audience,” said Dr. Rahul Kushwah, COO Cultivar. “We believe trading on the OTCQB will help us enhance liquidity by providing our current and future US investors with a trading platform. Our PredictMedix artificial intelligence technology platform will be of immense interest to US investors specially with the utility of our technology in healthcare in light of the current COVID-19 pandemic. “
The OTCQB Venture is the premier marketplace for entrepreneurial and development stage U.S. and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB Venture quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.
About Cultivar Holdings Inc:
Cultivar Holdings Inc. is an AI-powered company developing disruptive and cutting-edge tools for impairment and healthcare testing. It is intended that the Company’s impairment cannabis and alcohol detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice. The Company has partnered with Tech Mahindra and Hindalco to help expedite the launch of its impairment technology, as well as the prestigious Indian Institute of Technology.
The Company is also developing cutting edge screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, the Company is expanding its proprietary AI technology to screen for infectious diseases such as influenza and coronaviruses (COVID-19). Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.